Juvenile arthritis damage index predicts poor response to biological treatment: A prospective cohort study

Table 4 Comparative analysis of clinical parameters of patients whose juvenile arthritis damage index improved vs remained unchanged/deteriorated on biological disease-modified antirheumatic drugs therapy (end of study), n (%)

Parameter	Improved JADI, n = 41	Non-improved JADI, n = 19	P value
Presence of the JADI–A at the baseline	38 (92.7)	14 (73.7)	0.044
Baseline JADI-A, IQR	2 (1-5)	1 (0-2)	0.014
Patients with uveitis	2 (4.9)	4 (21.1)	0.05
Treatment with nbDMARDs at the EOS	40 (97.6)	14 (73.7)	0.004
Stable nbDMARD treatment during the study	39 (95.1)	12 (63.2)	0.001
Stable bDMARD treatment during the study	36 (87.8)	12 (63.2)	0.03
Bone osteonecrosis (JADI-E)	3 (7.3)	6 (31.6)	0.014
Eye damage (JADI-E)	0 (0)	2 (10.5)	0.034
MRI-confirmed bone erosions, n/n performed (%)	14/37 (37.8)	11/15 (73.3)	0.021
bDMARD treatment:			0.297
Etanercept	19 (46.3)	8 (42.1)
Golimumab	2 (4.9)	3 (15.8)
Adalimumab	14 (34.1)	8 (42.1)
Tofacitinib	4 (9.8)	0 (0)
Secukinumab	2 (4.9)	0 (0)

JADI-A: Juvenile arthritis damage index - articular damage; nbDMARDs: Non-biologic disease-modified antirheumatic drugs; EOS: End of study; bDMARD: Biologic disease-modified antirheumatic drugs; JADI-E: Juvenile arthritis damage index - extraarticular damage; MRI: Magnetic resonance imaging; IQR: Interquartile range.